With the bill limiting the participating generic makers to three consignees per consignor when conducting joint biological equivalence tests or clinical tests awaiting review by the National Assembly’s Legislation and Judiciary Committee., whether the opinion gap between the large pharmaceutical companies and small- and medium-sized pharmaceutical companies can be closed is gaining attention.

Despite the unanimous decision made by the Health and Welfare Committee, concerns have been rising on the influence the divided positions held by different sized pharmaceutical companies, which, if not resolved, may have on the process and result of the review conducted by the Legislation and Judiciary Co